主要不良肾脏事件定义的异质性:范围综述
该范围综述系统检索四大数据库,纳入122项以主要不良肾脏事件(MAKE)作为急性肾损伤(AKI)终点的研究,研究数量随时间增加。研究发现MAKE的组成标准与观察期存在显著异质性,部分研究甚至未描述标准;共采用13种观察期,以30天和90天最常见。持续肾功能障碍通过估算肾小球滤过率(34%)或血清肌酐浓度(48%)评估,但该组分在参数、界值和评估期方面共有37种不同定义;透析组分在评估期和透析需求持续时间(慢性 vs 临时)方面也高度异质。不同观察期可使MAKE发生率相差7%(四分位距:1.7-16.7%),不同透析组分定义可使MAKE发生率相差36.4%。作者认为需要专门讨论以建立统一可接受的MAKE操作标准。
要点
- 122项以MAKE为AKI终点的研究中,观察期共13种,30天与90天最常用,定义标准高度异质。
- 持续肾功能障碍组分用估算肾小球滤过率评估者占34%、用血清肌酐浓度评估者占48%,共37种不同定义。
- 透析组分在评估期和透析需求持续时间(慢性 vs 临时)方面存在显著异质性。
- 不同观察期可使MAKE发生率相差7%(四分位距:1.7-16.7%)。
- 不同透析组分定义可使MAKE发生率相差36.4%。
适用人群与场景
- 以MAKE作为AKI终点的研究人群,纳入122项研究
研究设计与关键结果
- 研究类型:系统范围综述,检索四大主要学术数据库,纳入122项以MAKE作为AKI终点的研究,研究数量随时间增加。
- 观察期:共采用13种不同观察期,30天和90天最常见。
- 持续肾功能障碍组分:通过估算肾小球滤过率评估者占34%,通过血清肌酐浓度评估者占48%;该组分在参数、界值标准和评估期方面共采用37种不同定义。
- 透析组分:在评估期和透析需求持续时间(慢性 vs 临时)方面显示显著异质性。
- MAKE发生率变异:不同观察期可使MAKE发生率相差7%(四分位距:1.7-16.7%);不同透析组分定义可使MAKE发生率相差36.4%。
- 部分研究缺乏对MAKE标准的描述。
证据类型、等级与局限
- 证据类型:系统范围综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需要专门讨论以建立统一且可接受的MAKE操作标准,涉及组分选择与应用标准、观察期以及未来AKI及相关疾病试验的报告标准。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Acute kidney injury (AKI) is associated with persistent renal dysfunction, the receipt of dialysis, dialysis dependence, and mortality. Accordingly, the concept of major adverse kidney events (MAKE) has been adopted as an endpoint for assessing the impact of AKI. However, applied criteria or observation periods for operationalizing MAKE appear to vary across studies. To evaluate this heterogeneity for MAKE evaluation, we performed a systematic scoping review of studies that employed MAKE as an AKI endpoint. Four major academic databases were searched, and we identified 122 studies with increasing numbers over time. We found marked heterogeneity in applied criteria and observation periods for MAKE across these studies, with some even lacking a description of criteria. Moreover, 13 different observation periods were employed, with 30 days and 90 days as the most common. Persistent renal dysfunction was evaluated by estimated glomerular filtration rate (34%) or serum creatinine concentration (48%); however, 37 different definitions for this component were employed in terms of parameters, cut-off criteria, and assessment periods. The definition for the dialysis component also showed significant heterogeneity regarding assessment periods and duration of dialysis requirement (chronic vs temporary). Finally, MAKE rates could vary by 7% [interquartile range: 1.7-16.7%] with different observation periods or by 36.4% with different dialysis component definitions. Our findings revealed marked heterogeneity in MAKE definitions, particularly regarding component assessment and observation periods. Dedicated discussion is needed to establish uniform and acceptable standards to operationalize MAKE in terms of selection and applied criteria of components, observation period, and reporting criteria for future trials on AKI and related conditions.
参考来源
- Maeda A, Inokuchi R, Bellomo R, et al. Heterogeneity in the definition of major adverse kidney events: a scoping review. Intensive Care Med. 2024. PMID: 38801518. doi:10.1007/s00134-024-07480-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。